Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2005-11-15
2005-11-15
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S192100, C514S008100, C530S352000
Reexamination Certificate
active
06964768
ABSTRACT:
A method for treating inflammatory joint diseases by inhibiting cadherin-11 mediated cellular function using a cadherin-11 modulating agent is provided. Also provided are screening assays for identifying pharmaceutical lead compounds capable of modulating cellular functions of cadherin-11 such as cell proliferation, apoptosis, factor secretion, and binding of cadherin-11 to cadherin-11 counter-receptor inhibiting binding of cadherin-11 to its counter-receptor either in the context of a cell or in soluble form.
REFERENCES:
patent: 5597725 (1997-01-01), Suzuki
patent: 5639634 (1997-06-01), Suzuki
patent: 5646250 (1997-07-01), Suzuki
patent: 5708143 (1998-01-01), Suzuki
patent: 5798224 (1998-08-01), Suzuki
patent: 5886026 (1999-03-01), Hunter et al.
patent: 6086877 (2000-07-01), Nishioka et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6787136 (2004-09-01), Brenner et al.
patent: WO 93/21302 (1993-10-01), None
patent: WO 98/02452 (1998-01-01), None
patent: WO 98/25946 (1998-06-01), None
patent: WO 98/49560 (1998-11-01), None
patent: WO 99/35166 (1999-07-01), None
Ngo J.T, Marks J., Karplus M., Computational complexity, protein structure prediction, and the Levinthal paradox in The Protein Folding Problem. ch. 14, pp. 491-494, Birkhauser, 1994.
Hoffmann et al. Cloning and expression analysis of a novel mesodermally expressed cadherin. Dev Biol. May 1995;169(1):337 46.
Branch, A.D., “A Good Antisense Molecule Is Hard to Find”,Trends Biochem Sci., Feb. 1998, vol. 23, No. 2, pp. 45-50.
Cepek, K. et al., “Integrin αEβ7Mediates Adhesion of T Lymphocytes to Epithelial Cells1,”The Journal of Immunology, Apr. 15, 1993, vol. 150, No. 8, pp. 3459-3470, Baltimore, MD, USA.
Falcini, F. et al., “Cadherins Expression in Autoimmune Diseases,”Arthritis Rheum., 1997, 40(Supp),. p. S283.
Jorgensen, C. et al., “In Vivo Migraion on Radiolabelled Lymphocytes in Rheumatoid Synovial Tissue Engrafted in SCID Mice: Implication of β2 and β7-Integrin,”J. Rheumatol. 1996, vol. 23, pp. 32-35.
Kahan, B.D., “Immunosuppressive therapy”,Curr. Opin. Immunol., 1992, vol. 4, No. 5, pp. 553-560.
Maccalman, C. et al., “Regulated Expression of Cadherin-11 in Human Epithelial Cells: A Role for Cadherin-11 in Trophoblast-Endometrium Interactions?,”Developmental Dynamics, 1996, vol. 206, pp. 201-211.
Mountain, A., “Gene Therapy: The First Decade”,Trends Biotechnol., Mar. 2000, vol. 18, No. 3, pp. 119-128.
Tanihara, H. et al., “Cloning of Five Human Cadherins Clarifies Characteristic Features of Cadherin Extracellular Domain and Provides Further Evidence for Two Structurally Different Types of Cadherin,”Cell Adhesion and Communications, 1994, vol. 2, pp. 15-26, Harwood Academic Publishers GmbH, USA.
Trollmo, C. et al., “Expression of the Mucosal Lymphocyte Integrin αEβ7and its Ligand E-Cadherin in the Symposium of Patients with Rheumatoid Arthritis,”Scand. J. Immunol., 1996, vol. 44, pp. 293-298.
Valencia, X. et al., “Cadherin-11 Mediates Adhesion Type B Synoviocytes in Rheumatoid Arthritis,”Arthritis&Rheumatism, Sep. 1999, p. S89, vol. 42, No. 9 suppl., NY, NY, USA, Abstract 111.
Valencia, X. et al., “Identification of Cadherin-11 in Type B Synoviocyters Derived from Rheumatoid Arthritis Patients,” Abstract Submission Form—ACR 62nd National Meeting, Nov. 8-12, 1998, San Diego, CA.
Van Noort, J.M. et al., “Cell Biology of Autoimmune Diseases”,Int. Rev. Cytol., 1998, vol. 178, pp. 127-206.
Brenner Michael B.
Valencia Xavier
Chan Christina
Haddad Maher
The Brigham & Women's Hospital, Inc.
Wolf Greenfield & Sacks P.C.
LandOfFree
Methods and compositions for treatment of inflammatory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treatment of inflammatory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treatment of inflammatory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3489213